Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk
- PMID: 40050430
- DOI: 10.1038/s41588-025-02074-9
Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk
Abstract
Atrial fibrillation (AF) is a prevalent and morbid abnormality of the heart rhythm with a strong genetic component. Here, we meta-analyzed genome and exome sequencing data from 36 studies that included 52,416 AF cases and 277,762 controls. In burden tests of rare coding variation, we identified novel associations between AF and the genes MYBPC3, LMNA, PKP2, FAM189A2 and KDM5B. We further identified associations between AF and rare structural variants owing to deletions in CTNNA3 and duplications of GATA4. We broadly replicated our findings in independent samples from MyCode, deCODE and UK Biobank. Finally, we found that CRISPR knockout of KDM5B in stem-cell-derived atrial cardiomyocytes led to a shortening of the action potential duration and widespread transcriptomic dysregulation of genes relevant to atrial homeostasis and conduction. Our results highlight the contribution of rare coding and structural variants to AF, including genetic links between AF and cardiomyopathies, and expand our understanding of the rare variant architecture for this common arrhythmia.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: P.T.E. has received sponsored research support from Bayer AG, Bristol Myers Squibb, Pfizer and Novo Nordisk, and he has consulted for Bayer. S.A.L. is a full-time employee of Novartis Institutes of BioMedical Research as of 18 July 2022. S.A.L. previously received sponsored research support from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Fitbit, Medtronic, Premier and IBM and has consulted for Bristol Myers Squibb, Pfizer, Blackstone Life Sciences and Invitae. B.M.P. serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. M.H.C. has received grant funding from GSK and Bayer, and speaking or consulting fees from AstraZeneca, Illumina and Genentech. C.M.H. receives research support from Tempus Labs, outside the scope of the present work. S.M.D. receives in kind research support from Novo Nordisk and personal consulting fees, outside the scope of the current research. D.C. receives consulting fees from Roche Diagnostics and Trimedics, and speaker fees from Servier and BMS/Pfizer. M.K. receives consulting fees from Roche Diagnostics. N.A.M. reports involvement in clinical trials with Amgen, Ionis, Pfizer, Novartis and AstraZeneca without personal fees, payments or increase in salary. C.T.R. provides consultancies with Anthos, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen and Pfizer. M.S.S. provides Consultancies with Amgen, Anthos Therapeutics, AstraZeneca, Bristol Myers Squibb, DalCor, Dr. Reddy’s Laboratories, IFM Therapeutics, Intarcia, Merck, Moderna, Novo Nordisk and Silence Therapeutics. R.S. has received lecture fees and advisory board fees from BMS/Pfizer outside this work. L.M.R. is a consultant for the TOPMed Administrative Coordinating Center through WeStat. M.K. reports personal fees from Bayer, Böhringer Ingelheim, Pfizer BMS, Daiichi Sankyo, Medtronic, Biotronik, Boston Scientific, Johnson & Johnson and Roche, and grants from Bayer, Pfizer, Boston Scientific, BMS, Biotronik and Daiichi Sankyo. L.-C.W. has received research support from IBM to the Broad Institute. C.R. is supported by a grant from Bayer to the Broad Institute focused on the development of therapeutics for cardiovascular disease. The remaining authors declare no competing interests.
References
Publication types
MeSH terms
Grants and funding
- K24HL105780/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- U01 AG068221/AG/NIA NIH HHS/United States
- K08HL153950/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 75N92019D00031/HL/NHLBI NIH HHS/United States
- 18SFRN34110082/American Heart Association (American Heart Association, Inc.)
- R01HL141989/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 648131/EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
- 847770/EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council)
- 18SFRN34230127/American Heart Association (American Heart Association, Inc.)
- R01HL157635/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 1U01AG068221-01A1/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01HL147148/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01HL111314/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01HL155197/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 9SFRN34830063/American Heart Association (American Heart Association, Inc.)
- 1U01AG058589-01A1/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 2019-0526/Hjärt-Lungfonden (Swedish Heart-Lung Foundation)
- R01HL092577/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R35HL135818/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 18SFRN34250007/American Heart Association (American Heart Association, Inc.)
- IRC15-0067/Stiftelsen för Strategisk Forskning (Swedish Foundation for Strategic Research)
- R01HL137927/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 32473B_176178/Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
- R25 EB031572/EB/NIBIB NIH HHS/United States
- AA/18/2/34218/British Heart Foundation (BHF)
- 1R01HL164824-01/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- HL113338/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01HL111024/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01HL141901/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- PG/20/22/35093/British Heart Foundation (BHF)
- HL116690/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 961045/American Heart Association (American Heart Association, Inc.)
- 18SFRN34110067/American Heart Association (American Heart Association, Inc.)
- P01HL158505/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- R01HL089856/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- IK2-CX001780/U.S. Department of Veterans Affairs (Department of Veterans Affairs)
- 349-2006-237/Vetenskapsrådet (Swedish Research Council)
- K08HL159346/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- DP2 HL157540/HL/NHLBI NIH HHS/United States
- 17K07251/MEXT | Japan Society for the Promotion of Science (JSPS)
- 2009-1039/Vetenskapsrådet (Swedish Research Council)
- 32003B_197524/Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
- R01 HL167072/HL/NHLBI NIH HHS/United States
- 03-007-2022-0035/Hartstichting (Dutch Heart Foundation)
- 33CS30_177520/Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
- JP18H02804/MEXT | Japan Society for the Promotion of Science (JSPS)
- 2019-0354/Svenska Sällskapet för Medicinsk Forskning (Swedish Society for Medical Research)
- 19SFRN34830063/American Heart Association (American Heart Association, Inc.)
- 2021-02273/Vetenskapsrådet (Swedish Research Council)
- 18SFRN34110067./American Heart Association (American Heart Association, Inc.)
- PG/17/30/32961/British Heart Foundation (BHF)
- 33CS30_148474/Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (Swiss National Science Foundation)
- R01HL149352/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 1R01HL139731/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 2R01HL127564-05A1/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 20CDA35260081/American Heart Association (American Heart Association, Inc.)
- HL-093613/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- 1R01HL128914/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- HL43680/Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)
- Ki 731/4-1/Deutsche Forschungsgemeinschaft (German Research Foundation)
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous